Stocks and Investing
Stocks and Investing
Fri, February 23, 2024
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
David Lebowitz Maintained (BBIO) at Strong Buy with Increased Target to $46 on, Feb 23rd, 2024
David Lebowitz of Citigroup, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Increased Target from $42 to $46 on, Feb 23rd, 2024.
David has made no other calls on BBIO in the last 4 months.
There are 3 other peers that have a rating on BBIO. Out of the 3 peers that are also analyzing BBIO, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $37 on, Wednesday, January 31st, 2024
These are the ratings of the 2 analyists that currently disagree with David
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $47 on, Monday, January 29th, 2024
- Josh Schimmer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $50 on, Monday, January 22nd, 2024
Contributing Sources